Combination preparation for the dietary treatment of gastrointestinal complaints caused by Helicobacter pylori infections

A capsule combining sulforaphane, curcumin, and a probiotic addresses the limitations of existing Helicobacter pylori treatments by offering a synergistic approach that effectively targets and supports gastric health, providing lasting relief.

DE202024105876U1Active Publication Date: 2024-12-05ALCUS MED GMBH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
DE202024105876
Authority / Receiving Office
DE · DE
Patent Type
Utility models
Current Assignee / Owner
Priority Date
2023-11-16
Filing Date
2024-10-11
Publication Date
2024-12-05
Estimated Expiration
2034-10-31

AI Technical Summary

Technical Problem

Current treatments for Helicobacter pylori infections, including antibiotic combinations and probiotics, fail to provide a significant and lasting improvement, often leading to reinfection and antibiotic resistance.

Method used

A capsule formulation containing sulforaphane, curcumin, and a probiotic, with sulforaphane derived from broccoli extract, curcumin from Curcuma longa, and optionally piperine, designed for synergistic action against Helicobacter pylori, enhancing gastric mucosa protection and intestinal health.

Benefits of technology

The combination effectively targets Helicobacter pylori with germicidal and anti-inflammatory effects, supporting the gastric microbiota and providing a sustained therapeutic benefit.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Capsule containing at least i. Sulforaphane and / or a precursor thereof, ii. Curcumin, and iii. a probiotic.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF THE INVENTION

[0001] The invention comprises a combination preparation for special medical purposes, preferably for the dietary treatment of stomach complaints caused by Helicobacter pylori infections. The invention relates to a capsule containing at least the active ingredients sulforaphane and / or a precursor thereof, curcumin, and a probiotic. BACKGROUND OF THE INVENTION

[0002] With a prevalence of approximately 50% worldwide, Helicobacter pylori infection is one of the most common chronic bacterial infections.

[0003] Helicobacter pylori infections are thought to be responsible for a number of gastric diseases associated with increased gastric acid secretion. These include, for example, type B gastritis, gastric ulcers, and duodenal ulcers. Testing for Helicobacter pylori infection is therefore an essential part of diagnosing gastric diseases.

[0004] Chronic infection with Helicobacter pylori is a risk factor for the development of gastric cancer and MALT lymphoma. Furthermore, Helicobacter pylori has been associated with many other diseases, such as idiopathic chronic urticaria, chronic immune thrombocytopenia, etiologically unexplained iron deficiency anemia, and Parkinson's disease.

[0005] Eradication therapy for Helicobacter pylori usually consists of a combination of a proton pump inhibitor and at least two antibiotics, as antibiotic monotherapies are not sufficiently effective. However, eradication often fails due to reinfection via oral plaque. Antibiotic resistance is also a potential cause of treatment failure.

[0006] WO2020198808A1 describes a probiotic composition containing sulforaphane to promote intestinal health.

[0007] EP0709098A1 describes a pharmaceutical composition containing piperine for increased bioavailability.

[0008] WO2019051565A1 describes an anti-inflammatory dietary supplement which contains, among other ingredients, curcumin and piperine.

[0009] However, none of these therapeutic approaches has yet been able to achieve significant and sustained improvement in Helicobacter pylori infection.

[0010] Accordingly, there is neither a general cure nor any preparations for long-term improvement of basic symptoms of a Helicobacter pylori infection of the stomach. SUMMARY OF THE INVENTION

[0011] The above-mentioned problem is solved by the combination preparation or capsule of the present invention.

[0012] In particular by a capsule containing at least the active ingredients i. Sulforaphane and / or a precursor thereof, ii. Curcumin, and iii. a probiotic.

[0013] Specifically, the capsule is characterized in that the sulforaphane and / or a precursor thereof is contained as broccoli extract, preferably as broccoli seed extract or as broccoli sprout extract.

[0014] Specifically, the capsule is characterized in that the broccoli extract contains at least 5% sulforaphane and / or a precursor thereof, preferably at least 10%.

[0015] Specifically, the capsule is characterized in that it contains sulforaphane and / or a precursor thereof in an amount of 10 - 30 mg, preferably in an amount of 10 to 20 mg.

[0016] The capsule is specifically characterized by the fact that the precursor of sulforaphane is glucoraphanin.

[0017] The capsule is specifically characterized by the fact that it also contains the enzyme myrosinase.

[0018] Specifically, the capsule is characterized by the fact that curcumin is an extract of Curcuma longa, preferably the extract of Curcuma longa contains at least 90% curcuminoids.

[0019] Specifically, the capsule is characterized in that curcumin is contained in an amount of 1 - 200 mg, preferably in an amount of 40 to 100 mg, even more preferably in an amount of 45 or 90 mg.

[0020] The capsule is specifically characterized by the fact that it also contains piperine.

[0021] In a special embodiment, the capsule contains at least the active ingredients i. Sulforaphane and / or a precursor thereof, ii. Curcumin, iii. Piperine, and iv. a probiotic.

[0022] Specifically, the capsule is characterized by containing piperine in an amount of 0.10 - 2.50 mg, preferably in an amount of 1.3 mg.

[0023] The capsule is specifically characterized by the fact that the probiotic is present in an amount of at least 1×10 9 cfu, preferably in an amount of 4×10 9 up to 14×10 9cfu, even more preferably in an amount of 4.4×10 9 cfu or an amount of 13.2×10 9 cfu.

[0024] Specifically, the capsule is characterized in that the probiotic is contained in an amount of 5 - 300 mg, preferably in an amount of 20 to 150 mg, even more preferably in an amount of 44 or 132 mg.

[0025] Specifically, the capsule is characterized in that the probiotic is selected from the group consisting of Lactobacillus spp., preferably Lactobacillus acidophilus, Lactobacillus rhamnosus, and Lactobacillus casei; Lactococcus lactis; Bifidobacterium spp., preferably Bifidobacterium infantis, Bifidobacterium breve, and Bifidobacterium longum; Streptococcus spp., preferably Streptococcus thermophilus; Saccharomyces spp., preferably Saccharomyces boulardii; and a combination thereof.

[0026] The capsule is specifically characterized by the fact that it is an immediate release capsule.

[0027] Specifically, the capsule is characterized in that it contains at least one pharmaceutically or dietary acceptable excipient and / or additive.

[0028] Specifically, the capsule is characterized in that the excipient and / or additive is selected from fillers, lubricants, preservatives, antioxidants, disintegrants, binders, thickeners, colorants, sweeteners, or flavorings.

[0029] According to a specific embodiment, the capsule contains 11 mg sulforaphane, 45 mg curcumin, and 44 mg Lactobacillus acidophilus.

[0030] According to another specific embodiment, the capsule contains 30 mg sulforaphane, 90 mg curcumin, 1.3 mg piperine, and 132 mg Lactobacillus acidophilus.

[0031] The capsule is specifically characterized by the fact that it also contains ascorbic acid.

[0032] The capsule is specifically characterized by the fact that it contains ascorbic acid in an amount of 1 - 80 mg.

[0033] Specifically, the capsule is used to produce a medicine to treat stomach and intestinal problems.

[0034] Specifically, the capsule is used to manufacture a medicine to treat symptoms caused by Helicobacter pylori infection.

[0035] The capsule is specifically used as a medicine, food supplement, or dietary food.

[0036] In particular, the capsule offers the advantage that the active ingredients can develop their synergistic effects by taking them together in one capsule. Specifically, both sulforaphane and curcumin have germicidal effects on Helicobacter pylori, with curcumin also possessing anti-inflammatory and antioxidant properties. Sulforaphane also inhibits the bacterial enzyme urease, which is produced by Helicobacter pylori to protect against the acidic environment of the stomach. Lactobacillus acidophilus is a beneficial bacterium naturally occurring in the stomach and intestines. It competes with Helicobacter pylori for colonization sites in the gastric mucosa and, on the other hand, supports the microbiota, which is generally weakened by concurrent antibiotic use.

[0037] Specifically, one dose is one capsule. A daily dose comprises at least one dose, i.e., one capsule.

[0038] Specifically, the daily dose of the capsule includes 1, 2, 3, 4, 5, 6, or more capsules. It is best to take one capsule twice daily, whole, with plenty of water. These capsules are best taken before breakfast and dinner. DETAILED DESCRIPTION OF THE INVENTION

[0039] Specific terms as used in the description have the following meaning.

[0040] The term "immediate release" refers to a solid dosage form with immediate release of the active ingredient, consisting of a capsule shell and filling. An immediate release is therefore not enteric-coated.

[0041] Sulforaphane, also known by the chemical name 1-isothiocyanato-4-methylsulfinylbutane, is an isothiocyanate. Sulforaphane is found primarily in broccoli, Brussels sprouts, and cauliflower. For several years, research has been conducted into its potential use in cancer therapy, arthritis, and respiratory diseases. A precursor to sulforaphane is glucoraphanin.

[0042] Glucoraphanin is a mustard oil glycoside (glucosinolate) found in various cruciferous plants, particularly in brassicas such as broccoli. Sulforaphane is formed during enzymatic hydrolysis of glucoraphanin, for example, by the plant's own myrosinase.

[0043] In the capsule, sulforaphane can also be present as a precursor of glucoraphanin or as a mixture of sulforaphane and glucoraphanin.

[0044] In one embodiment of the invention, a capsule comprises broccoli extract containing the sulforaphane and / or a precursor thereof.

[0045] In one embodiment of the invention, a capsule comprises broccoli seed extract containing the sulforaphane and / or a precursor thereof.

[0046] In one embodiment, a capsule comprises at least 100, 200, 300, 400, 500, 600, 700, or 800 mg of broccoli seed extract. Preferably, a capsule comprises at least 200, 500, or 800 mg of broccoli seed extract.

[0047] In one embodiment of the invention, a capsule comprises broccoli sprout extract containing the sulforaphane and / or a precursor thereof.

[0048] In one embodiment, a capsule comprises at least 100, 200, 300, 400, 500, 600, 700, or 800 mg of broccoli sprout extract. Preferably, a capsule comprises at least 200, 500, or 800 mg of broccoli sprout extract.

[0049] In one embodiment of the invention, the broccoli extract is a broccoli seed extract or a broccoli sprout extract.

[0050] In one embodiment of the invention, the broccoli extract contains sulforaphane and / or a precursor thereof in a range of 5-20%, 5-15%, 10-20%, or 10-15%. Preferably, the broccoli extract contains at least 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, or more of sulforaphane and / or a precursor thereof, preferably at least 10%.

[0051] In one embodiment of the invention, the capsule contains sulforaphane and / or a precursor thereof in an amount of 5-50, 5-45, 5-40, 5-35, 5-30, 5-25, 5-20, 5-15, 5-10, 10-50, 10-45, 10-40, 10-35, 10-30, 10-25, 10-20, 10-15, 20-50, 20-45, 20-40, 20-35, 20-30, or 20-25 mg. The capsule preferably contains sulforaphane and / or a precursor thereof in an amount of 10 - 30 mg, preferably in an amount of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or 30 mg.

[0052] In one embodiment of the invention, the capsule contains sulforaphane and glucoraphanin.

[0053] In one embodiment of the invention, the capsule contains sulforaphane or glucoraphanin.

[0054] Myrosinase is a plant-derived enzyme that catalyzes the conversion of glucoraphanin to sulforaphane. Myrosinase is found primarily in cruciferous vegetables (Brassicaceae), such as mustard, Brussels sprouts, and radishes, as well as in caper plants (Capparaceae), such as capers.

[0055] In one embodiment of the invention, the capsule contains myrosinase from broccoli extract, mustard powder, or nasturtium.

[0056] In one embodiment of the invention, the capsule contains broccoli extract, mustard powder, or nasturtium which contain myrosinase.

[0057] In one embodiment of the invention, the capsule contains myrosinase in an amount of 1-20, 1-15, 1-10, 5-20, 5-15, 5-10, 5-9, 5-8, 6-20, 6-15, 6-10, 6-9, or 6-8 mg. Preferably, the capsule contains myrosinase in an amount of 5-10 mg, more preferably in an amount of at least 7 mg.

[0058] In a special embodiment, the capsule contains 7.8 mg myrosinase.

[0059] In one embodiment of the invention, the capsule contains broccoli extract, wherein the broccoli extract contains myrosinase in a concentration of 4% by weight.

[0060] Curcumin is the main component of turmeric, Curcuma longa L., a member of the ginger family. It is native to India and Southeast Asia and has been traditionally used for thousands of years, primarily as a digestive aid and for bile duct disorders. It is also used for food preservation and as a yellow dye for textiles. Ground turmeric is a key ingredient in curry powder. Key components of turmeric are curcuminoids, which, in addition to curcumin, also include demethoxycurcumin, bisdemethoxycurcumin, and cyclocurcumin (curcumin I to IV).

[0061] The various effects of curcumin and curcuminoids have been intensively researched for several years. To date, anti-inflammatory, immunomodulatory, antioxidant, antiseptic, analgesic, antiproliferative, cytotoxic, and antitumor properties have been demonstrated, among others. Pharmacokinetic studies on the properties of curcumin show that it is poorly absorbed after oral administration, and only traces of the compound are found in the blood, while the majority is excreted in the feces. Therefore, curcumin is only found in low concentrations in the blood.

[0062] In one embodiment of the invention, the capsule contains an extract of Curcuma longa, which contains curcumin. In a preferred embodiment, the extract of Curcuma longa contains at least 90% curcuminoids.

[0063] In one embodiment of the invention, the capsule contains curcumin in an amount of 1-200, 10-200, 20-200, 30-200, 40-200, 50-200, 60-200, 1-250, 10-250, 20-250, 30-250, 40-250, 50-250, or 60-250 mg.

[0064] In one embodiment of the invention, the capsule contains at least 1, 5, 10, 50, 100, 150, 200, or 250 mg of curcumin. Preferably, one capsule contains 60, 70, 80, or 90 mg of curcumin. Specifically, one capsule contains approximately 60 or 90 mg of curcumin.

[0065] Oral ingestion of curcumin allows for local presence and topical pharmacological availability of curcumin on the gastric mucosa. Therefore, orally ingested curcumin can exert the aforementioned pharmacological properties on the gastric mucosa and can be used, for example, to treat bacteria residing there, such as H. pylori. To increase the concentration of curcumin in the blood, this capsule also contains piperine.

[0066] Piperine is the main alkaloid of black pepper (Piper nigrum) and is responsible for the spice's pungent taste. Piperine can be produced synthetically from piperidine and piperic acid, but can also be extracted from black pepper with ethanol and then crystallized. Like all pungent substances, piperine stimulates metabolism and secretion (saliva, digestive juices) and has antimicrobial effects. Furthermore, piperine increases the bioavailability of various substances after oral administration by inhibiting first-pass metabolism through the liver, leading to increased absorption. Specifically, piperine increases the bioavailability of drugs by inhibiting glucuronidation in the liver and small intestine. Piperine is known to increase the serum concentration, extent of absorption, and bioavailability of curcumin by up to 20-fold in both rats and humans.Piperine can therefore be administered together with curcumin to increase the concentration of curcumin in the blood. A capsule of the present invention preferably contains Bioperine® black pepper extract 95% piperine.

[0067] In one embodiment of the invention, the capsule contains piperine in an amount of 0.05-3.0, 0.10-2.50, 0.10-2.00, 0.10-1.50, 0.10-1.00, 0.20-3.00, 0.20-2.50, 0.20-2.00, 0.20-1.50, 0.20-1.00, 0.30-3.00, 0.30-2.50, 0.30-2.00, 0.30-1.50, 0.30-1.00, 0.40-3.00, 0.40-2.50, 0.40-2.00, 0.40-1.50, 0.40-1.00, 0.50-3.00, 0.50-2.50, 0.50-2.00, 0.50-1.50, 0.50-1.00, 0.60-3.00, 0.60-2.50, 0.60-2.00, 0.60-1.50, 0.60-1.00, 0.70-3.00, 0.70-2.50, 0.70-2.00, 0.70-1.50, 0.70-1.00, 0.80-3.00, 0.80-2.50, 0.80-2.00, 0.80-1.50, or 0.80-1.00 mg.

[0068] In one embodiment of the invention, the capsule contains at least 0.05, 0.10, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 0.90, 1.00, 1.50, 2.00, 2.50, or 3.00 mg of piperine. Preferably, a capsule contains 0.70, 0.80, 0.81, 0.82, 0.83, 0.84, 0.85, 0.86, 0.87, 0.88, 0.89, 0.9, 1.0, 1.1, 1.2, 1.3, or 1.4 mg of piperine. Specifically, a capsule contains 0.87 or 1.3 mg of piperine.

[0069] The term "probiotic" refers to living microorganisms that, when administered in sufficient numbers, can exert a health-promoting effect on the host. Probiotic microorganisms primarily include representatives of the lactobacilli, bifidobacteria, and yeasts such as Saccharomyces boulardii. A probiotic can be grown in pure culture in a fermenter / bioreactor and then freeze-dried for further processing.

[0070] Preferably, one capsule contains at least 1×10 8 , 1×10 9 , 4.4×10 9 , 8.8×109 , 13.2×10 9 , 1×10 10 , 1×10 11 or 1×10 12 colony forming units (cfu) per capsule of the probiotic, preferably in an amount of at least 4.4×10 9 , 8.8×10 9 , or 13.2×10 9 cfu. Specifically, the capsule contains 4.4×10 9 cfu of the probiotic. Specifically, the capsule contains 8.8×10 9 cfu of the probiotic. Specifically, the capsule contains 13.2×10 9 cfu of the probiotic. Accordingly, one capsule contains at least 40, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, or more mg of the probiotic, preferably 44, 88, or 132 mg.

[0071] In one embodiment, the capsule contains at least 1, 2, 3, 4, or 5 probiotics selected from the group consisting of Lactobacillus spp., Lactococcus lactis, Bifidobacterium spp., Streptococcus spp., and Saccharomyces spp..

[0072] In one embodiment, the capsule contains at least 1, 2, 3, 4, 5, 6, 7, 8, or 9 probiotics selected from the group consisting of Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactococcus lactis, Bifidobacterium infantis, Bifidobacterium breve, Bifidobacterium longum, Streptococcus thermophilus, and Saccharomyces boulardii.

[0073] The term "Lactobacillus spp." refers to the bacterial genus Lactobacillus from the Lactobacillaceae family. Members of the genus Lactobacillus are gram-positive bacteria; they do not form endospores and are incapable of active movement. Lactobacillus species are predominantly rod-shaped, with cells occurring singly or in chains. However, cocci-shaped variants can also occur.

[0074] "Lactobacillus acidophilus," or also called "L. acidophilus," refers to a bacterial species of the genus Lactobacillus. Lactobacillus acidophilus is a facultative anaerobic, Gram-positive rod that homofermentatively ferments glucose into lactic acid without producing any gases. It grows up to 45°C (some strains up to 48°C), and has diverse nutrient requirements for the culture medium.

[0075] "Lactobacillus rhamnosus," or "L. rhamnosus," refers to a species of bacteria in the genus Lactobacillus. Lactobacillus rhamnosus is a Gram-positive, medium-length, rod-shaped bacterium. A single cell is 2.0–4.0 µm long and 0.8–1.0 µm wide. Light microscopy reveals individual cells and cell chains. The bacterium lacks flagella for active movement and cannot form survival forms such as endospores.

[0076] "Lactobacillus casei," or also called "L. casei," refers to a bacterial species of the genus Lactobacillus. Lactobacillus casei is a rod-shaped, Gram-positive bacterium. It belongs to the smaller Lactobacillus species and grows in the form of shorter or longer rods with mostly rounded corners and an average size of 0.9 µm in diameter and 2 µm in length. They usually occur singly or in pairs, less frequently in short chains.

[0077] "Lactococcus lactis," or "L. lactis," refers to a species of bacteria in the genus Lactococcus. Lactococcus lactis is a Gram-positive bacterium used in the production of buttermilk, curds, kefir, and cheese. The cells of Lactococcus lactis are cocci that form pairs or short chains and, depending on the growth conditions, appear oval and range in length from 0.5 to 1.5 µm. They do not form survival forms such as endospores and are non-motile.

[0078] The term "Bifidobacterium spp." refers to the genus Bifidobacteria. Bifidobacteria, identical to the genus Bifidobacterium, belong to the family Bifidobacteriaceae, which are Gram-positive, non-motile, non-spore-forming, predominantly anaerobic rod-shaped bacteria and are often club-shaped ("coryneform").

[0079] "Bifidobacterium infantis," or also called "B. infantis," refers to a subspecies of Bifidobacterium longum. B. infantis, along with other bifidobacteria, is one of the first natural inhabitants of the large intestine and is among the most common representatives of the intestinal flora in breastfed newborns. B. infantis is marketed worldwide as a dietary supplement in a wide variety of products. B. infantis adheres firmly to the intestinal mucosa and multiplies rapidly there. When B. infantis converts sugar, it produces lactic and acetic acid, which lowers the pH value in its environment. This prevents pathogens from establishing themselves and multiplying, or only to a very limited extent. B. infantis also produces B vitamins, such as folic acid, thiamin (vitamin B1), pyridoxine (vitamin B6), biotin (vitamin B7), and niacin. The normal, non-pathogenic bacterial culture of the gastrointestinal tract, appendix and vagina includes, among others, B. bifidum, B.adolescentis, B. breve, B. longum and B. infantis.

[0080] “Bifidobacterium breve” refers to a species of bacteria in the genus Bifidobacterium.

[0081] “Bifidobacterium longum” refers to a species of bacteria in the genus Bifidobacterium.

[0082] The term "Streptococcus spp." refers to the genus Streptococci. Streptococci are bacteria of the genus Streptococcus in the family Streptococcaceae. They are coccal (approximately spherical), preferentially arranged in chains, Gram-positive, and aerotolerant.

[0083] Streptococcus thermophilus, also known as S. thermophilus, refers to a subspecies of Streptococcus salivarius and is a Gram-positive, facultatively anaerobic, and spherical lactic acid bacterium.

[0084] The term “Saccharomyces spp.” refers to a yeast species of the family Saccharomycetaceae and forms a genus in the division of Ascomycetes.

[0085] "Saccharomyces boulardii," or "S. boulardii," refers to a yeast species of the genus Saccharomyces. Saccharomyces boulardii is also considered a subspecies or variety of Saccharomyces cerevisiae (Saccharomyces cerevisiae var. boulardii).

[0086] In a preferred embodiment, the capsule contains Lactobacillus acidophilus.

[0087] In a preferred embodiment, the capsule contains sulforaphane, curcumin, and Lactobacillus acidophilus. The sulforaphane can also be present as a precursor, glucoraphanin, or as a mixture of sulforaphane and glucoraphanin.

[0088] In another embodiment, the capsule contains sulforaphane, curcumin, piperine, and Lactobacillus acidophilus. The sulforaphane can also be present as a precursor, glucoraphanin, or as a mixture of sulforaphane and glucoraphanin. In another embodiment, the capsule contains sulforaphane, curcumin, Lactobacillus acidophilus, and myrosinase. The sulforaphane can also be present as a precursor, glucoraphanin, or as a mixture of sulforaphane and glucoraphanin.

[0089] In another embodiment, the capsule contains sulforaphane, curcumin, piperine, Lactobacillus acidophilus, and myrosinase. The sulforaphane can also be present as a precursor, glucoraphanin, or as a mixture of sulforaphane and glucoraphanin.

[0090] “Ascorbic acid” is also known as vitamin C. In the invention, the term “ascorbic acid” also includes the salt of ascorbic acid ascorbate.

[0091] One capsule contains ascorbic acid in an amount of 1-80, 10-80, 20-80, 30-80, 40-80, 50-80, 60-80, 70-80, 1-70, 1-60, 1-50, 1-40, 1-30, 1-20, 1-10, 10-80, 10-70, 10-60, 10-50, 10-40, 10-30, 10-20, 20-80, 20-70, 20-60, 20-50, 20-40, 20-30, 30-80, 30-70, 30-60, 30-50, 30-40, 40-80, 40-70, 40-60, 40-50, 50-80, 50-70, 50-60, 60-80, 60-70, or 70-80 mg.

[0092] In one embodiment of the invention, the capsule contains 1, 4, 5, 10, 20, 30, 40, 50, 60, 70, or 80 mg of ascorbic acid.

[0093] In one embodiment of the invention, the capsule contains myrosinase and vitamin C. Vitamin C acts as a catalyst in the enzymatic conversion of glucoraphanin to sulforaphane by myrosinase.

[0094] In one embodiment, the capsule contains sulforaphane, curcumin, Lactobacillus acidophilus, and ascorbic acid. The sulforaphane can also be present as a precursor, glucoraphanin, or as a mixture of sulforaphane and glucoraphanin.

[0095] In one embodiment, the capsule contains sulforaphane, curcumin, Lactobacillus acidophilus, myrosinase, and ascorbic acid. The sulforaphane can also be present as a precursor, glucoraphanin, or as a mixture of sulforaphane and glucoraphanin.

[0096] In one embodiment, the capsule contains sulforaphane, curcumin, piperine, Lactobacillus acidophilus, myrosinase, and ascorbic acid. The sulforaphane can also be present as a precursor, glucoraphanin, or as a mixture of sulforaphane and glucoraphanin.

[0097] In one embodiment, the daily dose comprises 1, 2, 3, 4, 5, 6, or more capsules. Preferably, one capsule is taken twice daily, whole, with plenty of water. Specifically, these capsules are taken before breakfast and dinner.

[0098] Depending on the concentration of active ingredient in one capsule, the number of capsules per daily dose may vary.

[0099] In one embodiment, the preferred daily dose of sulforaphane is 44 mg per day. Specifically, the daily dose comprises 4 capsules, each containing 11 mg of sulforaphane. Preferably, 2 capsules are taken twice daily.

[0100] In another embodiment, the preferred daily dose of sulforaphane comprises 60 mg per day. Specifically, the daily dose comprises 2 capsules, each capsule containing 30 mg of sulforaphane. Alternatively, the daily dose comprises 3 capsules, each capsule containing 20 mg of sulforaphane. Alternatively, the daily dose comprises 6 capsules, each capsule containing approximately 10 mg, preferably 11 mg, of sulforaphane.

[0101] In one embodiment, the preferred daily dose of curcumin comprises 180 mg per day. Specifically, the daily dose comprises 4 capsules, each containing 45 mg of curcumin. Alternatively, the daily dose comprises 2 capsules, each containing 90 mg of curcumin. Alternatively, the daily dose comprises 3 capsules, each containing 60 mg of curcumin. Preferably, 2 capsules are taken twice daily, each containing 45 mg of curcumin.

[0102] In one embodiment, the preferred daily dose of piperine comprises 2.6 mg per day. Specifically, the daily dose comprises 4 capsules, each capsule containing 0.65 mg of piperine. Alternatively, the daily dose comprises 2 capsules, each capsule containing 1.3 mg of piperine. Alternatively, the daily dose comprises 3 capsules, each capsule containing 0.87 mg of piperine. Preferably, 2 capsules are taken twice daily, each capsule containing 0.65 mg of piperine.

[0103] In one embodiment, the preferred daily dose of probiotic comprises 176 mg or 17.6 × 10 9 cfu probiotic per day. Specifically, the daily dose includes 4 capsules, with each capsule containing 44 mg or 4.4×10 9 Contains cfu probiotic. Two capsules are preferably taken twice daily.

[0104] In another embodiment, the preferred daily dose of probiotic comprises 264 mg per day. Specifically, the daily dose comprises 2 capsules, with one capsule containing 132 mg or 13.2×10 9 cfu probiotic. Specifically, a daily dose includes 3 capsules, with one capsule containing 88 mg or 8.8×10 9 cfu probiotic contains.

[0105] In another embodiment, the preferred daily dose of probiotic comprises 176 mg per day, with one capsule containing 264 mg of probiotic for stability reasons. Specifically, the daily dose comprises 4 capsules, with one capsule containing 66 mg or 6.6×10 9 cfu probiotic contains.

[0106] In another embodiment, the preferred daily dose of probiotic comprises 132 mg per day, with one capsule containing 264 mg of probiotic for stability reasons. Specifically, the daily dose comprises 2 capsules, with one capsule containing 132 mg or 13.2×10 9 cfu probiotic. Specifically, a daily dose includes 3 capsules, with one capsule containing 88 mg or 8.8×10 9 cfu probiotic contains.

[0107] The term "combination preparation" refers to a preparation containing at least the active ingredients sulforaphane and / or its precursor, curcumin, and a probiotic. Optionally, the combination preparation also contains piperine. The sulforaphane can also be present as the precursor glucoraphanin or as a mixture of sulforaphane and glucoraphanin. In addition, other pharmaceutically or dietary-compatible excipients and / or additives may be included in the preparation. The combination preparation can be a capsule.

[0108] The term "pharmaceutically or dietary acceptable adjuvants and / or additives" refers to substances (excipients) useful in the manufacture of a pharmaceutical composition or formulation that are generally safe, non-toxic, and neither biologically nor otherwise undesirable, and can be used for both veterinary use and human pharmaceutical agents. According to the IPEC definition, an excipient is any component of a pharmaceutical composition other than an active ingredient that has been intentionally incorporated into the pharmaceutical composition. Pharmaceutical compositions of the present invention contain, as active ingredients, the ingredients mentioned herein: sulforaphane and / or a precursor thereof, curcumin, and a probiotic, as well as, optionally, piperine. These ingredients may be associated with one or more pharmaceutically acceptable carriers or excipients.The excipient used is typically one suitable for administration to human subjects or other mammals. In preparing the compositions, the active ingredient is usually mixed with an excipient and enclosed in a carrier, which may be in the form of a capsule. When the excipient serves as a diluent, it may be a solid, semi-solid, or liquid material that acts as a vehicle, carrier, or medium for the active ingredient. Thus, the combination preparation may be in one of the following forms: soft or hard gelatin capsule, pill, powder, sachet, or sterile-packaged powder.

[0109] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methylcellulose. The formulation may additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preservatives such as methyl and propyl hydroxybenzoates; sweeteners; and flavoring agents. The compositions of the invention may be formulated to provide rapid, sustained, or delayed release of the active ingredient after administration to the patient by using methods known in the art.The amount of carriers, excipients and / or additives in the pharmaceutical composition can be varied or widely adjusted depending on the specific application, the efficacy of the specific compound and the desired concentration.

[0110] The pharmaceutically or dietary-compatible excipient and / or additive can be a "filler." Fillers primarily serve to achieve a target weight during weight-based production, depending on the number and size of the capsules and the quantity / weight of the active ingredient. Examples of fillers include lactose, cellulose, cellulose powder, starch, sucrose, polyethylene glycols (macrogols, PEG), and polyethylene oxides (PEO).

[0111] The pharmaceutically or dietary-acceptable excipient and / or additive may be a "lubricant." This excipient is often also called a lubricant and can be used, among other things, to facilitate swallowing the capsule. Examples of lubricants include polyethylene glycols (PEGs, macrogols), polyethylene oxides (PEOs), talc, or magnesium stearate.

[0112] The pharmaceutically or dietary-acceptable excipient and / or additive may be a "preservative." Preservatives are used to extend the shelf life of the pharmaceutical compound. Examples of preservatives include PHB esters, benzalkonium chloride, benzyl alcohol, or thimerosal.

[0113] Pharmaceutically or dietary-compatible excipients and / or additives can be "antioxidants." Oxidation-sensitive substances decompose during storage as a result of a process known as autoxidation. This reaction is triggered by atmospheric oxygen and catalyzed by UV light and heavy metals. Heat and free radicals also promote autoxidation. Even small amounts of antioxidants can reduce or even prevent autoxidation. These substances are more easily oxidized than the active ingredients and excipients they are protecting. For this reason, they react in their place but are consumed over time. Oxidation-sensitive active ingredients can therefore be protected with antioxidants. Examples of antioxidants include butylhydroxytoluene, all-rac-α-tocopherol, and EDTA.

[0114] Pharmaceutically or dietary-compatible excipients and / or additives can be "disintegrants." Disintegrants serve, for example, to draw moisture into the tablet core and, through swelling, accelerate the disintegration of the tablet. They are therefore often referred to as disintegration accelerators. Examples of disintegrants include modified starches such as carboxymethyl starch, croscarmellose, or sodium bicarbonate.

[0115] Pharmaceutically or dietary-compatible excipients and / or additives can be "binders." Binders, in particular, help to enlarge the particles in a pharmaceutical compound, can reduce the dust content in the mass to be processed, and, in the case of further processing into tablets or capsules, can improve plastic formability. The choice of binder can influence the porosity, disintegration time, and solubility of a pharmaceutical compound. Examples of binders include starches, guar gum, xanthan gum, alginate, carrageenan, pectin, tragacanth, polyacrylic acids, polyvinylpyrrolidone, highly dispersed silicon dioxide, or substituted cellulose ethers such as methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose.

[0116] Pharmaceutically or dietary-compatible excipients and / or additives may be "thickeners." Thickeners are substances that, even when added in small amounts, cause a significant increase in the viscosity of liquids. Their effect is based on swelling (e.g., gelatin for gels) or the formation of associative bonds. Examples of thickeners include cellulose such as cellulose powder, microcrystalline cellulose, and cellulose derivatives such as hydroxypropylmethylcellulose and ethylcellulose, pectins, guar gum, karaya, locust bean gum, carrageenan, polyethylene glycol, and polyacrylic acid (Carbopol™).

[0117] Pharmaceutically or dietary-acceptable excipients and / or additives may be "sweeteners." Sweeteners are often used in pharmaceutical compounds, for example, to reduce any bitterness and to make oral administration easier and more pleasant. Examples of sweeteners include sucrose, sorbitol, and sweeteners such as sodium saccharin and cyclamate.

[0118] Pharmaceutically or dietary-compatible excipients and / or additives may be "flavoring agents." Flavoring agents are often used in pharmaceutical compounds to adjust the taste and make oral administration easier and more pleasant. Various flavors are often used for taste correction.

[0119] The term "powder" refers to loose pharmaceutical powders, which are mixtures of finely divided medicinal substances in dry form that are ultimately processed into capsules, film-coated tablets, creams, or other medicinal forms. These powders contain one or more active ingredients, with or without excipients. A distinction is made between single-dose (= single-dose) powders and multi-dose powders.

[0120] The term "granules" refers to grain-like structures consisting of coarsely ground solid substances. Granules consist of powder particles cemented together by a binding agent. They are often more soluble in water than powder and are usually taken with plenty of liquid.

[0121] The term "dietary food" generally refers to a food for special medical purposes that meets the specific nutritional needs of individuals suffering from, or suffering from malnutrition as a result of, certain diseases, disorders, or conditions. "Food for special medical purposes" is a category of foods for particular nutritional uses that are specially processed or formulated and intended for the dietary treatment of patients and are to be used under medical supervision.Their purpose is the exclusive or partial nutrition of patients with limited, impaired or disturbed ability to ingest, digest, absorb, metabolise or excrete ordinary foods or certain nutrients contained therein or their metabolites, or of patients with other medically determined nutritional needs for whose dietary treatment modification of the normal diet, other foods for a special diet or a combination of both are not sufficient.

[0122] The use of this combination preparation as a dietary food is preferably used for the dietary treatment of stomach and intestinal complaints, in particular stomach and intestinal complaints caused by an infection with Helicobacter pylori.

[0123] The term ‘food supplement’ refers to foodstuffs intended to supplement, but not replace, the normal diet and which consist of single or multiple concentrates of nutrients or other substances with a nutritional or physiological effect and which are marketed in dosed form, i.e. in the form of, for example, capsules, lozenges, tablets, pills and other similar presentations, powder sachets, liquid ampoules, bottles with dropper attachments and similar presentations of liquids and powders for ingestion in measured small quantities.

[0124] Helicobacter pylori (H. pylori) infection is a common bacterial infection that can cause gastritis, peptic ulcers, and certain types of stomach cancer. Symptoms of Helicobacter pylori infection include indigestion and upper abdominal pain or discomfort.

[0125] Numerous case reports and individual clinical studies demonstrate the antibacterial effect of broccoli on Helicobacter pylori. The natural content of sulforaphane, the antibacterial component of broccoli, is approximately 1 mg / 20 g of raw broccoli, which, with a therapeutically effective daily dose of 60 mg of sulforaphane, corresponds to approximately 1 kg of raw broccoli. In cooked or otherwise thermally prepared broccoli, the sulforaphane levels are correspondingly lower.

[0126] The curcumin content of dried turmeric, Curcuma longa, is approximately 3%, while curry or other turmeric-containing spices contain significantly less (approximately 0.3%). A therapeutically effective daily dose of 180 mg of curcumin would correspond to the intake of 6 g of turmeric powder (or 60 g of curry).

[0127] The advantages of the capsule according to the invention lie, on the one hand, in the simplified, concentrated and tasteless intake of the ingredients sulforaphane and curcumin, and, on the other hand, in the combined administration of both ingredients in one capsule. EXAMPLES 1. Composition of the product "CoCurmin Broccoli" with piperine: Ingredients per daily dose of active ingredient, for example, per 2 or 3 capsules Broccoli seed extract contains sulforaphane 585 mg 58.5 mg Turmeric root extract (Curcuma longa) contains total curcuminoids of which curcumin 257.1 mg 244.3 mg 180 mg Lactobacillus acidophilus* 132 mg (13.2 × 10 9 CFU) Black pepper extract contains piperine 2.7 mg 2.6 mg Ingredients: Broccoli seed extract, capsule shell hydroxypropylmethylcellulose, bulking agent microcrystalline cellulose, turmeric root extract, Lactobacillus acidophilus, medium-chain triglycerides from coconut, color chlorophyllin copper complex, black pepper extract. * Bacterial culture overdosed by 100% for stability reasons (264 mg bacterial culture included) 2. Composition of the product “CoCurmin Broccoli” without piperine, with ascorbic acid: Ingredients per capsule Broccoli seed extract contains sulforaphane 220 mg 11 mg (5% of the extract) Turmeric root extract (Curcuma longa) contains total curcuminoids of which curcumin 64.28 mg 61.075 mg (95% of the extract) 45 mg Probiotic Lactobacillus acidophilus* 44 mg (4,4 × 10 9 CFU) Ascorbic acid 4 mg Ingredients: Broccoli seed extract, capsule shell hydroxypropylmethylcellulose, bulking agent microcrystalline cellulose, turmeric root extract, Lactobacillus acidophilus, medium-chain triglycerides from coconut, color chlorophyllin-copper complex, ascorbic acid. * Bacterial culture overdosed by 50% for stability reasons (66 mg bacterial culture included) 3. Composition of the product “CoCurmin Broccoli” with piperine: Ingredients per daily dose of active ingredient (recommended intake 2×2 capsules, total 4 capsules per day) Broccoli seed extract contains sulforaphane 880 mg 44 mg Turmeric root extract (Curcuma longa) contains total curcuminoids of which curcumin 257.1 mg 244.3 mg 180 mg Lactobacillus acidophilus* 176 mg (17.6 × 10 9 CFU) Vitamin C 16 mg Black pepper extract contains piperine 2.7 mg 2.6 mg Ingredients: Broccoli seed extract, capsule shell hydroxypropylmethylcellulose, bulking agent microcrystalline cellulose, turmeric root extract, Lactobacillus acidophilus, medium-chain triglycerides from coconut, color chlorophyllin copper complex, black pepper extract. * Bacterial culture overdosed by 50% for stability reasons (264 mg bacterial culture included) QUOTES CONTAINED IN THE DESCRIPTION

[0000] This list of documents submitted by the applicant was generated automatically and is included solely for the convenience of the reader. This list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions. Cited patent literature

[0000] WO2020198808A1

[0006] EP0709098A1

[0007] WO2019051565A1

[0008]

Claims

[1] Capsule containing at least i. Sulforaphane and / or a precursor thereof, ii. Curcumin, and iii. a probiotic. [2] Capsule according to claim 1, characterized by that the sulforaphane and / or a precursor thereof is contained as broccoli extract, preferably as broccoli seed extract or as broccoli sprout extract. [3] Capsule according to claim 2, characterized by that the broccoli extract contains at least 5% sulforaphane and / or a precursor thereof, preferably at least 10%. [4] Capsule according to one of claims 1 to 3, characterized by that it contains sulforaphane and / or a precursor thereof in an amount of 10 - 30 mg, preferably in an amount of 10 to 20 mg. [5] Capsule according to one of claims 1 to 4, characterized by that the precursor of sulforaphane is glucoraphanin. [6] Capsule according to one of claims 1 to 5, characterized by that it also contains the enzyme myrosinase. [7] Capsule according to one of claims 1 to 6, characterized by that it also contains piperine. [8] Capsule according to one of claims 1 to 7, characterized by that curcumin is an extract of Curcuma longa, preferably the extract of Curcuma longa contains at least 90% curcuminoids. [9] Capsule according to one of claims 1 to 8, characterized by that curcumin is contained in an amount of 1 - 200 mg, preferably in an amount of 45 or 90 mg. [10] Capsule according to one of claims 1 to 9, characterized by that piperine is contained in an amount of 0.10 - 2.50 mg, preferably in an amount of 1.3 mg. [11] Capsule according to one of claims 1 to 10, characterized by that the probiotic is present in an amount of at least 1×10 9 cfu, preferably in an amount of 4.4 × 10 9 cfu or 13.2 × 10 9 cfu. [12] Capsule according to one of claims 1 to 11, characterized bythat the probiotic is contained in an amount of 5 - 150 mg, preferably in an amount of 44 or 132 mg. [13] Capsule according to one of claims 1 to 12, characterized by that the probiotic is selected from the group consisting of Lactobacillus spp., preferably Lactobacillus acidophilus, Lactobacillus rhamnosus, and Lactobacillus casei; Lactococcus lactis; Bifidobacterium spp., preferably Bifidobacterium infantis, Bifidobacterium breve, and Bifidobacterium longum; Streptococcus spp., preferably Streptococcus thermophilus; Saccharomyces spp., preferably Saccharomyces boulardii; and a combination thereof. [14] Capsule according to one of claims 1 to 13, characterized by that it is an immediate release capsule. [15] Capsule according to one of claims 1 to 14, characterized bythat it contains at least one pharmaceutically or dietary acceptable excipient and / or additive, preferably selected from fillers, lubricants, preservatives, antioxidants, disintegrants, binders, thickeners, colorants, sweeteners, or flavorings. [16] Capsule according to any one of claims 1 to 15, containing 11 mg sulforaphane, 45 mg curcumin and 44 mg Lactobacillus acidophilus. [17] Capsule according to any one of claims 7 to 15, containing 30 mg sulforaphane, 90 mg curcumin, 1.3 mg piperine, and 132 mg Lactobacillus acidophilus. [18] Capsule according to one of claims 1 to 17, characterized by that it additionally contains ascorbic acid, preferably in an amount of 1 - 80 mg. [19] Use of the capsule according to any one of claims 1 to 18 for the manufacture of a medicament for the treatment of stomach and intestinal complaints. [20] Use of the capsule according to any one of claims 1 to 18 for the manufacture of a medicament for the treatment of complaints caused by an infection with Helicobacter pylori. [21] Food supplement containing the capsule according to any one of claims 1 to 18. [22] Dietary food containing the capsule according to any one of claims 1 to 18.

Citation Information

Patent Citations

  • Compositions containing piperine

    EP0709098A1

  • Composition and uses thereof

    WO2019051565A1

  • Methods and compositions for promoting health in a subject

    WO2020198808A1